Why Silence Therapeutics plc’s (SLN) Stock Is Down 6.51%
As of Wednesday, September 23, Silence Therapeutics plc’s SLN share price has dipped by 6.51%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Commentary & Analysis
Why Silence Therapeutics plc’s (SLN) Stock Is Down 6.66%
As of Tuesday, September 15, Silence Therapeutics plc’s SLN share price has dipped by 6.66%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Silence Therapeutics plc’s (SLN) Stock Is Down 5.04%
As of Tuesday, September 08, Silence Therapeutics plc’s SLN share price has dipped by 5.04%, which has investors questioning if this is right time to buy.Jenna Brashear
Is Silence Therapeutics plc (SLN) Overvalued?
We dive into why Silence Therapeutics plc (SLN) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Jenna Brashear
Why Silence Therapeutics plc’s (SLN) Stock Is Up 29.46%
As of Monday, August 10, Silence Therapeutics plc’s SLN share price has surged by 29.46%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | SLN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $673.1 | $257.9 | 41% |
|
| Shares Out (Mil) | 47.2 | 54.3 | 46% |
|
| Institutional Ownership | 69.3% | 92.9% | 42% |
|
| Float (Mil) | 48.2 | 41.4 | 46% |
|
| Beta | 1.44 | 0.95 | 81% |
|
| Avg Daily Volume (000s) | 886 | 674 | 66% |
|
| Price Change (52-week) |
117.5% | 51.5% | 95% |
|
| Growth | SLN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (39.7%) | 13.2% | 0% |
|
| Net Income (5yr) | (14.8%) | (10.1%) | 26% |
|
| EPS (5yr) | (2.9%) | 15.8% | 27 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (45.7%) | (15.6%) | 9% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 2 | 2 | |
| Current EPS | ($0.090) | ($0.365) | ($0.380) | |
| Month Ago EPS | ($0.089) | ($0.352) | ($0.371) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.100) | ($0.400) | ($0.390) | |
| Year/Year Chg | (65.4%) | (80.5%) | (73.9%) | |
| Financials | SLN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $37 | 1% |
|
| Net Income (TTM) (Mil) | ($60) | ($43) | 15% |
|
| EPS (TTM) | ($1.269) | ($1.600) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($42) | ($32) | 10% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $666 | $174 | 37% |
|
| Valuation | SLN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 13.80 | 2.51 | 93% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | SLN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 85.9% | 68.9% | 92% |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (44.1%) | (47.7%) | 13% |
|
| ROE | (90.4%) | (54.9%) | 10% |
|
| Liabilities to Assets | 63.8% | 29.1% | 58% |
|
| F-Score | 2 | 3 | 7% |
|
Silence Therapeutics plc did not pass any screens on 9/25/2026.
